StreetInsider.com News Articles

Form 8-K OCULAR THERAPEUTIX, INC For: Oct 14

Fri, 16 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261016/27198119.html

Form 4 OCULAR THERAPEUTIX, INC For: Oct 08 Filed by: Anderman Todd

Tue, 13 Oct 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20261013/27181837.html

UBS Starts Ocular Therapeutix (OCUL) at Buy

Mon, 12 Oct 2026 02:20:45 -0400

UBS analyst Alice Nettleton initiates coverage on Ocular Therapeutix (NASDAQ: OCUL) with a Buy rating and a price target of $14.00.

The analyst comments: “We initiate coverage of Ocular Therapeutix (OCUL) with a Buy rating and $14 PT. We believe lead asset Axpaxli is a differentiated long-acting retinal therapy with the potential to unlock substantial value in patient populations where extended treatment durability is particularly important (potential $20B US TAM). We model a $3.3B total 2035 sales forecast versus Street expectations of $2.9B. In a recent Phase 3 trial in wet age-related macular degeneration (wAMD), Axpaxli demonstrated superiority to a single

UBS Starts Ocular Therapeutix (OCUL) at Buy

Mon, 12 Oct 2026 02:20:45 -0400

UBS analyst Alice Nettleton initiates coverage on Ocular Therapeutix (NASDAQ: OCUL) with a Buy rating and a price target of $14.00.

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 09 Oct 2026 07:00:00 -0400

BEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to fifteen newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards were granted effective as of October 5, 2026, and consist of non-statutory stock option awards to purchase up to

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 09 Oct 2026 07:00:00 -0400

The inducement equity awards were granted effective as of October 5, 2026, and consist of non-statutory stock option awards to purchase up to

Form 144 OCULAR THERAPEUTIX, INC Filed by: Anderman Todd

Thu, 08 Oct 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20261008/27167290.html

Top 4 Healthcare Stocks Backed by Raymond James Analysts

Thu, 08 Oct 2026 09:53:14 -0400

Investing.com -- Raymond James has identified its top stock picks in the healthcare sector, highlighting companies with upcoming clinical trial results and promising drug development programs. The firm’s Analyst Current Favorites list features biotechnology companies positioned for potential catalysts in 2025 and 2026.

The ranking represents current favorite stock ideas from Raymond James equity research analysts, with each analyst selecting one buy-rated idea from their coverage universe. The list includes companies rated either Strong Buy or Outperform.